

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**LISTING OF CLAIMS:**

**1-11. (cancelled)**

**12. (currently amended)** ~~Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of A method for treating vascular diseases related to endothelial and smooth muscle cells proliferation, said method comprising administering to a subject in need thereof the therapeutic agent of claim 16.~~

**13. (currently amended)** ~~Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation~~ The method according to claim 12, characterised in that ~~wherein the~~ vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage.

**14. (currently amended)** ~~Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation~~ The method according to claim 12,

~~characterised in that wherein the~~ vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage, including those events that occur after coronary and/or carotid angioplasty, with or without stent positioning, angiographic surgery, and surgery using catheters.

**15. (currently amended)** ~~Use of HMG box binding molecules. The method according to claim 12,~~ wherein said HMG box binding molecules ~~belong to~~ molecule is chosen from the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA.

**16. (currently amended)** ~~Therapeutic~~ A therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation ~~characterised in that it comprises,~~ said agent comprising a therapeutic active amount of a HMG box binding molecules molecule.

**17. (currently amended)** ~~Therapeutic~~ The therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation according to claim 16,  
wherein said ~~molecules belong to the group comprising~~ HMG box binding molecule is chosen from antibodies or antibodies fragments, inhibitors and four-way DNA and not sRAGE.

**18. (currently amended) Therapeutic**—The therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation—characterised in that it comprises, said agent comprising a therapeutic active amount of antagonist molecules having sequence homology with HMG box and being able to bind the—a functional HMG box binding domain of the receptor.

**19. (currently amended) Therapeutic**—The therapeutic agent according to claim 16, characterised in that it wherein said agent is released by catheters, surgical instruments implants or stents.